WO2008144223A2 - Composés triazolyl aminopyrimidine - Google Patents

Composés triazolyl aminopyrimidine Download PDF

Info

Publication number
WO2008144223A2
WO2008144223A2 PCT/US2008/062808 US2008062808W WO2008144223A2 WO 2008144223 A2 WO2008144223 A2 WO 2008144223A2 US 2008062808 W US2008062808 W US 2008062808W WO 2008144223 A2 WO2008144223 A2 WO 2008144223A2
Authority
WO
WIPO (PCT)
Prior art keywords
amino
ethyl
alkyl
mmol
methyl
Prior art date
Application number
PCT/US2008/062808
Other languages
English (en)
Other versions
WO2008144223A3 (fr
Inventor
Harold Burns Brooks
Joyce Z Crich
James Robert Henry
Hong Hu
Delu Jiang
Hong-Yu Li
William Thomas Mcmillen
Jason Scott Sawyer
Melissa Kate Slater
Yan Wang
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Priority to EA200971068A priority Critical patent/EA016781B1/ru
Priority to JP2010508500A priority patent/JP5248600B2/ja
Priority to KR1020097023340A priority patent/KR101131261B1/ko
Priority to AU2008254319A priority patent/AU2008254319B2/en
Priority to CN2008800157689A priority patent/CN101679395B/zh
Priority to EP08747731A priority patent/EP2155734A2/fr
Priority to US12/598,926 priority patent/US8063035B2/en
Priority to BRPI0811433A priority patent/BRPI0811433A2/pt
Priority to CA002691997A priority patent/CA2691997A1/fr
Priority to MX2009012228A priority patent/MX2009012228A/es
Publication of WO2008144223A2 publication Critical patent/WO2008144223A2/fr
Publication of WO2008144223A3 publication Critical patent/WO2008144223A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Plkl belongs to a small family of protein kinases characterized by a phosphoserine/threonine binding domain known as the polo box domain. Plkl plays a central role in the regulation of the cell cycle. Among other functions, Plkl is thought to regulate initiation, progression, and exit from mitosis, the stage when cancer cells divide. Consequently, blocking Plkl in cancer cells prevents their division or mitosis.
  • VELC ADE® is an antineoplastic agent that inhibits the 26S proteosome.
  • PIk inhibitors specifically target dividing cells and may be able to avoid the undesirable toxicities.
  • Inhibitors of Plkl are known in the art. See for example, WO 06/066172. Additionally, WO 06/021548 discloses certain dihydropteridinone analogs (e.g., BI- 2536) as inhibitors of Plkl.
  • BI-2536 is in phase II clinical trials but has high clearance (CL >1000 mL/min) and is dose limited by myelosupression in man.
  • the present invention provides novel triazolyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plkl. Certain of these compounds are believed to have improved potency over compounds disclosed in WO 06/066172.
  • R 1 is methyl, methoxy, hydroxy, amino, chloro, amino(Ci-C 4 alkyl), dimethylamino(Ci-C2 alkyl), (C 1 -C 2 alkyl)amino(Ci-C2 alkyl), aminocarbonyl(Ci-C3 alkyl), l-((l-amino)ethylcarbonylamino)ethyl, 2-(N-methylamino)ethoxy, 2- cyanoprop-2-yl, (2-hydroxy-2-methyl)-l-propyloxy, (2- hydroxy)ethylaminocarbonylmethyl, (l-fluoro)-(2-amino)ethyl, (l-fluoro)-(l-methyl)- (2-amino)ethyl, difluoromethyl, 1 -((2,2-difluoro)ethylamino)ethyl, difluoromethylcarbonyl, trifluoromethylcarbonyl
  • R 2 is hydrogen or amino provided that if R 2 is amino, R 1 and R 2 form a pyrrole ring fused to the phenyl; or if R 1 is amino, R 1 and R 2 can form either a pyrrole or a pyridine ring fused to the phenyl;
  • R 3 is hydrogen chloro, or fluoro
  • R 4 is hydrogen, methyl, chloro, or fluoro
  • R 5 is hydrogen, hydroxymethyl, or methyl
  • R 6 is hydrogen, hydroxymethyl, or methyl; or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method of treating cancer selected from the group consisting of non-small cell lung, oropharyngeal, esophageal, gastric, melanoma, epidermoid carcinoma of the skin, breast, ovarian, endometrial, colorectal, neuroglioma, glioblastoma, thyroid carcinoma, cervical, pancreatic, prostate, hepatoblastoma and non-Hodgkin lymphoma cancers in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable excipient, carrier, or diluent.
  • This invention also provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use as a medicament. Additionally, this invention provides use of a compound of Formula I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer.
  • these cancers are selected from the group consisting of non-small cell lung, oropharyngeal, esophageal, gastric, melanoma, epidermoid carcinoma of the skin, breast, ovarian, endometrial, colorectal, neuroglioma, glioblastoma, thyroid carcinoma, cervical, pancreatic, prostate, hepatoblastoma and non-Hodgkin lymphoma cancers.
  • this invention provides a pharmaceutical composition for treating cancer selected from the group consisting of non-small cell lung, oropharyngeal, esophageal, gastric, melanoma, epidermoid carcinoma of the skin, breast, ovarian, endometrial, colorectal, neuroglioma, glioblastoma, thyroid carcinoma, cervical, pancreatic, prostate, hepatoblastoma and non-Hodgkin lymphoma cancers comprising a compound of Formula I or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention also provides compounds of the Formula:
  • R 1 is methyl, methoxy, hydroxy, amino, chloro, amino(Ci-C 2 alkyl), dimethylaminomethyl, (C 1 -C 2 alkyl)amino(Ci-C 2 alkyl), aminocarbonylmethyl, 2-(N- methylamino)ethoxy, (2-hydroxy-2-methyl)-l-propyloxy, difluoromethyl, 2- (amino)ethoxy, 2-(hydroxy)ethoxy, 4-(hydroxy)piperidin-l-yl-methyl, [N-(2- hydroxy)ethyl-N-methyl] -aminomethyl, 2-(hydroxy)ethylsulfonyl, 1 - (amino)cyclopropyl, tetrahydrofur-2-yl, or (morpholin-4-yl)methyl;
  • R 2 is hydrogen or amino provided that if R 2 is amino, R 1 and R 2 form a pyrrole ring fused to the phenyl; or if R 1 is amino, R 1 and R 2 can form either a pyrrole or a pyridine ring fused to the phenyl;
  • R 3 is hydrogen or halo
  • R 4 is hydrogen or halo; or a pharmaceutically acceptable salt thereof.
  • (Ci-C 4 alkyl) means methyl, ethyl, w-propyl, isopropyl, w-butyl, isobutyl, sec-butyl, and tert-butyl.
  • (C 1 -C 3 alkyl) is included within the meaning Of(Ci-C 4 alkyl)” and means methyl, ethyl, w-propyl, and isopropyl.
  • (C 1 -C 2 alkyl) is included within the term “(Ci-C 4 alkyl)” and means methyl and ethyl.
  • halo means fluoro, chloro, bromo, and iodo.
  • a substituent is attached through an alkyl group such as ethyl, w-propyl, isopropyl, w-butyl, isobutyl, sec-butyl, or tert-butyl in the terms "amino(Ci-C 4 alkyl)" or "dimethylamino(Ci-C 2 alkyl)” or "(Ci-C 2 alkyl)amino(Ci-C 2 alkyl)", the attachment of the substituent may be through any carbon of the alkyl.
  • aminoethyl [amino(C 2 alkyl)] as an illustration, the following connectivities are intended.
  • the compounds of the present invention are capable of forming salts.
  • the compounds of the present invention are amines, and accordingly react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts.
  • Such pharmaceutically acceptable acid addition salts and common methodology for preparing them are well known in the art. See, e.g., P. Stahl, et ah, HANDBOOK OF PHARMACEUTICAL SALTS : PROPERTIES, SELECTION AND USE,
  • R 1 is amino(Ci-C 4 alkyl); b) R 1 is l-(amino)ethyl; c) R 2 is hydrogen; d) R 3 is fluoro; e) R 4 is fluoro; f) R 5 is hydrogen or methyl; g) R 5 is methyl; h) R 6 is hydrogen; i) R 1 is amino(Ci-C 4 alkyl), dimethylamino(Ci-C 2 alkyl), (Ci-C 2 alkyl)amino(Ci-C 2 alkyl), aminocarbonyl(Ci-C3 alkyl), 1-((1- amino)ethylcarbonylamino)ethyl, 2-cyanoprop-2-yl, (2-
  • R 6 is hydrogen; k) R 1 is amino(Ci-C 4 alkyl), dimethylamino(Ci-C 2 alkyl), (C 1 -C 2 alkyl)amino(Ci- C 2 alkyl), or (morpholin-4-yl)methyl; R 3 is fluoro; R 4 is fluoro;
  • R 5 is hydrogen or methyl; and R 6 is hydrogen; 1) R 1 is amino(Ci-C 4 alkyl), dimethylamino(Ci-C 2 alkyl), or (Ci-C 2 alkyl)amino(Ci-C2 alkyl); R 3 is fluoro; R 4 is fluoro;
  • R 5 is hydrogen or methyl; and R 6 is hydrogen; m) The is compound of Claim 1 wherein R 1 is 1 -(amino)ethyl, R 3 is fluoro, R 4 is fluoro, R 5 is hydrogen, and R 6 is hydrogen; and n) The compound of Claim 1 wherein R 1 is l-(amino)ethyl, R 3 is fluoro, R 4 is fluoro, R 5 is methyl, and R 6 is hydrogen.
  • Compound 5 in Scheme I is prepared by a palladium (0) coupling reaction between either starting material 1 with 2, or starting material 3 with 4.
  • a suitable palladium catalyst such as tetrakis(triphenylphosphine)-palladium(0) or [1,1 '- bis(diphenyl-phosphino)ferrocene]dichloropalladium(II) complex with DCM (1 : 1) [Pd(dppf)Cl 2 ].
  • Pd(dppf)Cl 2 is used in the presence of a base, such as sodium or potassium carbonate.
  • the reactions are carried out in a solvent, such as tetrahydrofuran (THF), dioxane, and water, generally, at temperatures of from about 100 0 C to 150 0 C using an oil bath or a microwave reactor.
  • THF tetrahydrofuran
  • Compound 5 is lithiated with lithium diiopropylamide in tetrahydrofuran (THF) and triisopropylborate in situ forming a benzo[b]thiophene boronate species followed by a palladium (0) coupling reaction with a 2,4-dichloropyrimidine (Compound 6) giving Compound 7.
  • the boronate is generally formed at a low temperature, such as -78 0 C.
  • the coupling reaction is followed immediately with conditions as described above for preparing Compound 5.
  • Compounds of the present invention are then prepared via a nucleophilic displacement reaction where Compound 7 is reacted with Compound 8.
  • Such reactions are carried out in a solvent, such as, w-butanol, dioxane, and N- methylpyrolidin-2-one (NMP).
  • a solvent such as, w-butanol, dioxane, and N- methylpyrolidin-2-one (NMP).
  • the reactions are carried out at temperatures of from about 120 0 C to 150 0 C using an oil bath or a microwave reactor.
  • About 2 equivalents of 2-(amino-ethyl)- 1,2,3 -triazole (Compound 8) are used.
  • Amine bases such as triethyl amine and diisopropylethyl amine are used as acid scavengers.
  • compounds of the present invention can be prepared by the Suzuki reaction between starting materials 2 and 9 or 4 and 10 with conditions described above.
  • (R)-tert-butylsulfinamine can be used both 1) as a chiral auxiliary via condensation with aldehydes to form sulfinimines followed further by stereoselective reactions, e.g., with (trifluoromethyl)trimethylsilane to form protected diastereomeric sulfinamides and 2) as an easily removable amino protection group once a diastereomeric sulfinamide has been isolated.
  • Some of the examples of the present invention are prepared from other examples of the present invention.
  • the skilled artisan will appreciate that in many circumstances, the order in which the moieties are introduced is not critical. The particular order of steps required to produce the compounds of the present invention can be dependent upon the particular compound being synthesized, the starting compound, and the relative lability of the substituted moieties.
  • N-( 1 -(2-Bromo-4-fluorophenyl)ethyl)-2,2-difluoroethanamine Add borane-THF complex (10.69 mL, 10.7 mmol) to a solution of N-(l-(2- bromo-4-fluorophenyl)ethyl)-2,2-difluoroacetamide (1.06 g, 3.56 mmol) in THF (3 mL). Reflux the mixture for 17 h. Quench with hydrochloric acid (5 ⁇ , 8 mL). Stir the solution for 1 h. Add saturated ⁇ aHC ⁇ 3. Dilute the mixture with DCM, wash with water and aqueous saturated sodium chloride. Separate the organic layer and dry over sodium sulfate. Filter and concentrate in vacuo to give the title compound (0.94 g, 93 %). MS (ES) m/z 282 [M+ 1] + .
  • Plkl has been shown to be over expressed in many human tumors, such as non-small cell lung, oropharyngeal, esophageal, gastric, melanoma, breast, ovarian, endometrial, colorectal, glioblastoma, papillary, pancreatic, prostate, hepatoblastoma and non-Hodgkin lymphoma cancers. Furthermore, Plkl expression has prognostic significance in non-small cell lung, oropharyngeal, esophageal, melanoma, colorectal, hepatoblastoma and non-Hodgkin lymphoma cancers (Strebhardt, K. and A. Ullrich.
  • Plkl phosphorylated substrates regulate progression of mitosis by coordinating centrosome maturation, entry into mitosis, sister chromatid separation and cytokinesis [Eckerdt F. Strebhardt K. Cancer Research. 66(14):6895-8, 2006; Strebhardt and Ullrich 2006; van de Weerdt, B. C. and R. H. Medema. Cell Cycle 5(8): 853-64 (2006)].
  • BI-2536 has demonstrated activity in preclinical models using HCTl 16, A549 and NCIH460 murine xenografts (Baum, A., P. Garin-Chesa, et al. (2006). #C191 In vivo activity of BI 2536, a potent and selective inhibitor of the mitotic kinase PLKl, in a range of cancer xenografts. AACR-N CI-EORTC International Conference on
  • Plkl cDNA may be directly linked at one of its termini with a polynucleotide sequence expressing a His ⁇ tag, such as the C-terminal FLAG-His ⁇ tag, and inserted into an appropriate expression vector, such as a pFastBacTM vector (Invitrogen) and transfected into an appropriate system, such as baculovirus similar to what has been reported by Yue-Wei Qian, et al, Science, 282, 1701 (1998) for xPlkkl.
  • a polynucleotide sequence expressing a His ⁇ tag such as the C-terminal FLAG-His ⁇ tag
  • an appropriate expression vector such as a pFastBacTM vector (Invitrogen) and transfected into an appropriate system, such as baculovirus similar to what has been reported by Yue-Wei Qian, et al, Science, 282, 1701 (1998) for xPlkkl.
  • the virus e.g., baculovirus bearing a Plkl-Flag-His ⁇ tag polynucleotide construct
  • a suitable host cell such as Sf9 cells.
  • the culture should be treated with okadaic acid (0.1 ⁇ M) for a sufficient period of time (e.g., 3 hours).
  • the Plkl-Flag-His ⁇ tag fusion is purified from cell pellets using a metal affinity resin, such as TALONTM using methods well known in the art.
  • Purified Plkl-Flag-His ⁇ tag fusion is stored in a suitable medium, such as 10 mM HEPES, 150 mM NaCl, 0.01% TRITON® X-100, 1 mM dithiothreitol (DTT), 10 % glycerol, pH 7.5, at -80 0 C in small aliquots until use.
  • a suitable medium such as 10 mM HEPES, 150 mM NaCl, 0.01% TRITON® X-100, 1 mM dithiothreitol (DTT), 10 % glycerol, pH 7.5, at -80 0 C in small aliquots until use.
  • the identity of the purified Plkl-Flag-His ⁇ tag fusion protein is confirmed by MALDI (Matrix-Assisted Laser Desorption/Ionization).
  • Human Cdc25C cDNA which may be obtained from any appropriate source, may be expressed in any convenient expression system, after which purification is effected by well known methods similar to that described by Bin Ouyang et al,
  • One convenient system involves overnight growth at 18 0 C of E.coli BL21 tranformed with the pGEX-2T vector (Amersham) into which the cDNA for human Cds25C has been engineered for induced expression using 1 mM isopropyl-beta-D-thiogalactopyranoside.
  • the expressed GST-Cdc25C(l-206), the substrate for PIk 1 may be purified (for example, by GLUTATHIONE
  • Plkl Inhibition Assay Plkl kinase reactions contain Plkl-Flag-His ⁇ tag fusion enzyme (0.2 ng/ ⁇ L) in a buffer containing 50 mM HEPES, pH 7.3, 1.0 mM dithiothreitol, 5.0 ⁇ M ATP, 10 mM MgCl 2 , 0.01% TRITON® X-100, 0.4 ⁇ Ci 33 P-ATP, and 0.06 ⁇ g/ ⁇ L GST- Cdc25c (1-206) peptide.
  • Compounds are provided as 10 mM stocks in DMSO.
  • Compounds are serially diluted 1 :3 in 20 % DMSO to create a 10-point concentration- response curve and subsequently are diluted 1:5 (20 ⁇ M to 0.001 ⁇ M final in 4 % final DMSO concentration) in the reaction mixture to determine compound activity.
  • the reaction is carried out at room temperature for 60 min and then quenched by adding 60 ⁇ L of 10.0 % H 3 PO 4 .
  • the reaction mixture (85 ⁇ L) is transferred to a 96 well phosphocellulose filter plate pre-wetted with 30 ⁇ L of 10.0 % H 3 PO 4 , incubated at room temperature for 20-30 min and then washed 3X with 0.5 % H 3 PO 4 .
  • HeLa Cells are plated at 200 cells/well in 96 well Beckman Dickinson BIOCOATTM plates, and are incubated in MEM (Minimum Essential Medium) with 10% FBS (Fetal Bovine Serum) in 37 0 C, 5 % CO 2 for 24 hours. Cells are treated by adding compound (in 0.25 % DMSO) to the medium, dosing at 10 points across the range 0.5 ⁇ M to 0.0098 ⁇ M.
  • cells are fixed, for example with the PREFERTM fixative for 30 min then are permeablized with 0.1% TRITON® XlOO in phospate buffered saline (PBS) solution for 15 min.
  • PBS phospate buffered saline
  • Cells are washed 3 times with PBS then digested with 50 ⁇ g/mL RNAse.
  • Primary antibody, anti-phosphohistone H3 Serine 10 is added at 1:500 in PBS with 1 % bovine serum albumin (BSA) to the cells over night at 4 0 C. After 3 PBS washes, cells are incubated with Alexa488 labeled secondary antibody for 1 hour at room temperature.
  • BSA bovine serum albumin
  • Fluorescence Plates are scanned with ACUMEN EXPLORERTM [Laser-scanning fluorescence microplate cytometer (comprising of 488 nm argon ion laser excitation and multiple photomultiplier tube detection), manufactured by TTP LABTECH LTD] to measure phosphohistone H3, DNA content and mitotic cells as measured by DNA condensation. Image analysis are based on cellular fluorescent signals for identifying cells in different subpopulations. pHH3(S10) positive cells are identified by mean intensity at 500-530 nm above the threshold.
  • Total intensity at 655-705 nm from propidium iodide/DNA is used to identify individual cells (cells with DNA content from 2N to 4N) and subpopulations in cell cycle (2N cells, 4N cells). Peak intensity at 575-640 nm is used to identify DNA condensation that is used as the marker to identify mitotic cells among 4N cells.
  • Assay outputs are percentage of each identified subpopulations, %pHH3, % 2N, %4N, %mitotic and total cell number.
  • the EC 50 is determined by curve fitting to a four parameter logistic for each output using ACTIVITY BASETM.
  • HCTl 16 cells which may be obtained from the American Type Culture Collection, may be seeded at -2000 cells/well in 96-well plates and allowed to attach overnight in a humidified CO 2 incubator at 37 0 C. Following the 20-24 hour incubation, half-log serially diluted compounds are added and the plates are returned to the incubator. After an appropriate length of exposure (e.g., 72 hours), cell proliferation is estimated using well-known methods. In one method, 10 ⁇ L of a tetrazolium salt, such as Alamar BlueTM is added to the cell plates. After an appropriate exposure to the dye, fluorescence (530 nm excitation, 580 nm emission) is determined.
  • a tetrazolium salt such as Alamar BlueTM
  • the resulting IC50 has a Minimum Significant Ratio (MSR) of 3.1.
  • MSR Minimum Significant Ratio
  • the compounds of the present invention are preferably formulated as pharmaceutical compositions administered by a variety of routes. Most preferably, such compositions are for oral or intravenous administration. Such pharmaceutical compositions and processes for preparing same are well known in the art. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (A. Gennaro, et al, eds., 19 th ed., Mack Publishing Co., 1995). The compounds of Formula I are generally effective over a wide dosage range.
  • dosages per day normally fall within the range of about 1 to about 10 mg/kg of body weight, preferably 2 to 6.5 mg/kg of body weight. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, and therefore the above dosage range is not intended to limit the scope of the invention in any way. It will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composés triazolyl aminopyrimidine utiles pour le traitement du cancer.
PCT/US2008/062808 2007-05-16 2008-05-07 Composés triazolyl aminopyrimidine WO2008144223A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EA200971068A EA016781B1 (ru) 2007-05-16 2008-05-07 Триазолиламинопиримидиновые соединения
JP2010508500A JP5248600B2 (ja) 2007-05-16 2008-05-07 トリアゾリルアミノピリミジン化合物
KR1020097023340A KR101131261B1 (ko) 2007-05-16 2008-05-07 트리아졸릴 아미노피리미딘 화합물
AU2008254319A AU2008254319B2 (en) 2007-05-16 2008-05-07 Triazolyl aminopyrimidine compounds
CN2008800157689A CN101679395B (zh) 2007-05-16 2008-05-07 ***基氨基嘧啶化合物
EP08747731A EP2155734A2 (fr) 2007-05-16 2008-05-07 Composés triazolyl aminopyrimidine
US12/598,926 US8063035B2 (en) 2007-05-16 2008-05-07 Triazolyl aminopyrimidine compounds
BRPI0811433A BRPI0811433A2 (pt) 2007-05-16 2008-05-07 compostos do tipo triazolil aminopirimidina
CA002691997A CA2691997A1 (fr) 2007-05-16 2008-05-07 Composes triazolyl aminopyrimidine
MX2009012228A MX2009012228A (es) 2007-05-16 2008-05-07 Compuesto de triazolil aminopirimidina.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93834707P 2007-05-16 2007-05-16
US60/938,347 2007-05-16

Publications (2)

Publication Number Publication Date
WO2008144223A2 true WO2008144223A2 (fr) 2008-11-27
WO2008144223A3 WO2008144223A3 (fr) 2009-02-05

Family

ID=39951591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/062808 WO2008144223A2 (fr) 2007-05-16 2008-05-07 Composés triazolyl aminopyrimidine

Country Status (15)

Country Link
US (1) US8063035B2 (fr)
EP (1) EP2155734A2 (fr)
JP (1) JP5248600B2 (fr)
KR (1) KR101131261B1 (fr)
CN (1) CN101679395B (fr)
AR (1) AR066473A1 (fr)
AU (1) AU2008254319B2 (fr)
BR (1) BRPI0811433A2 (fr)
CA (1) CA2691997A1 (fr)
CL (1) CL2008001323A1 (fr)
EA (1) EA016781B1 (fr)
MX (1) MX2009012228A (fr)
PE (1) PE20090216A1 (fr)
TW (1) TW200908981A (fr)
WO (1) WO2008144223A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010527364A (ja) * 2007-05-16 2010-08-12 イーライ リリー アンド カンパニー トリアゾリルアミノピリミジン化合物
WO2011024441A1 (fr) * 2009-08-25 2011-03-03 Oncotherapy Science, Inc. Ercc6l comme gènes cibles pour le diagnostic et la thérapie du cancer
WO2011025546A1 (fr) * 2009-08-31 2011-03-03 Massachusetts Institute Of Technology 1, 2, 3-triazole contenant des détecteurs de protéine kinase
US8063035B2 (en) 2007-05-16 2011-11-22 Eli Lilly And Company Triazolyl aminopyrimidine compounds
US8063212B2 (en) 2006-12-21 2011-11-22 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
US8101628B2 (en) 2006-12-21 2012-01-24 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
US8440835B2 (en) 2007-02-26 2013-05-14 Massachusetts Institute Of Technology Environmentally sensitive fluorophores
US8586570B2 (en) 2006-08-28 2013-11-19 Massachusetts Institute Of Technology Sox-based kinase sensor
WO2020068600A1 (fr) * 2018-09-24 2020-04-02 Rapt Therapeutics, Inc. Modulateurs de la protéase 7 de traitement spécifique de l'ubiquitine (usp7) et leurs utilisations
WO2021042169A1 (fr) * 2019-09-05 2021-03-11 The University Of Melbourne Inhibiteurs de nitrification

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN109415366B (zh) * 2016-06-23 2022-02-22 豪夫迈·罗氏有限公司 [1,2,3]***并[4,5-d]嘧啶衍生物
CN112341428A (zh) * 2020-11-04 2021-02-09 菏泽鸿特药业有限公司 一种噻吩-2-乙胺的生产方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007599A2 (fr) * 1988-02-09 1989-08-24 Georgia State University Foundation, Inc. Nouvelles diazines et leur procede de preparation
WO2006066172A1 (fr) * 2004-12-17 2006-06-22 Amgen, Inc. Composes d'aminopyrimidine et procedes d'utilisation correspondants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063192A1 (fr) 2003-01-10 2004-07-29 Pharmacopeia Drug Discovery, Inc. Derives de d'imidazolyl pyrimidine utilises comme modulateurs du recepteur de il-8
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
US7329764B2 (en) * 2003-07-31 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Substitute benzothiophene compounds
TW200800201A (en) 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds
CN101437519A (zh) 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
ATE479680T1 (de) 2006-12-21 2010-09-15 Lilly Co Eli Imidazolidinonylaminopyrimidinverbindungen zur behandlung von krebs
EP2125794B1 (fr) * 2006-12-21 2010-10-20 Eli Lilly & Company Composés imidazolidinonyl aminopyrimidine pour le traitement du cancer
CN101679395B (zh) 2007-05-16 2012-06-13 伊莱利利公司 ***基氨基嘧啶化合物
EP2155735A2 (fr) * 2007-05-16 2010-02-24 Eli Lilly And Company Composés triazolyl aminopyrimidine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989007599A2 (fr) * 1988-02-09 1989-08-24 Georgia State University Foundation, Inc. Nouvelles diazines et leur procede de preparation
WO2006066172A1 (fr) * 2004-12-17 2006-06-22 Amgen, Inc. Composes d'aminopyrimidine et procedes d'utilisation correspondants

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586570B2 (en) 2006-08-28 2013-11-19 Massachusetts Institute Of Technology Sox-based kinase sensor
US8063212B2 (en) 2006-12-21 2011-11-22 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
US8101628B2 (en) 2006-12-21 2012-01-24 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
US8440835B2 (en) 2007-02-26 2013-05-14 Massachusetts Institute Of Technology Environmentally sensitive fluorophores
US8063035B2 (en) 2007-05-16 2011-11-22 Eli Lilly And Company Triazolyl aminopyrimidine compounds
JP2010527364A (ja) * 2007-05-16 2010-08-12 イーライ リリー アンド カンパニー トリアゾリルアミノピリミジン化合物
US8114872B2 (en) 2007-05-16 2012-02-14 Eli Lilly And Company Triazolyl aminopyrimidine compounds
WO2011024441A1 (fr) * 2009-08-25 2011-03-03 Oncotherapy Science, Inc. Ercc6l comme gènes cibles pour le diagnostic et la thérapie du cancer
US8409820B2 (en) 2009-08-31 2013-04-02 Massachusetts Institute Of Technology Kinase sensors
WO2011025546A1 (fr) * 2009-08-31 2011-03-03 Massachusetts Institute Of Technology 1, 2, 3-triazole contenant des détecteurs de protéine kinase
WO2020068600A1 (fr) * 2018-09-24 2020-04-02 Rapt Therapeutics, Inc. Modulateurs de la protéase 7 de traitement spécifique de l'ubiquitine (usp7) et leurs utilisations
US11084829B2 (en) 2018-09-24 2021-08-10 Rapt Therapeutics, Inc. Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof
WO2021042169A1 (fr) * 2019-09-05 2021-03-11 The University Of Melbourne Inhibiteurs de nitrification
CN114616227A (zh) * 2019-09-05 2022-06-10 墨尔本大学 硝化抑制剂
AU2020341256B2 (en) * 2019-09-05 2023-01-19 The University Of Melbourne Nitrification inhibitors

Also Published As

Publication number Publication date
EP2155734A2 (fr) 2010-02-24
PE20090216A1 (es) 2009-02-28
CN101679395B (zh) 2012-06-13
CN101679395A (zh) 2010-03-24
EA016781B1 (ru) 2012-07-30
EA200971068A1 (ru) 2010-04-30
KR101131261B1 (ko) 2012-04-24
MX2009012228A (es) 2009-12-01
WO2008144223A3 (fr) 2009-02-05
AU2008254319B2 (en) 2012-04-19
BRPI0811433A2 (pt) 2016-03-22
KR20090130242A (ko) 2009-12-21
JP5248600B2 (ja) 2013-07-31
AR066473A1 (es) 2009-08-19
US8063035B2 (en) 2011-11-22
US20100087431A1 (en) 2010-04-08
CA2691997A1 (fr) 2008-11-27
TW200908981A (en) 2009-03-01
CL2008001323A1 (es) 2009-05-29
JP2010527365A (ja) 2010-08-12
AU2008254319A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
US8063035B2 (en) Triazolyl aminopyrimidine compounds
US8114872B2 (en) Triazolyl aminopyrimidine compounds
US8063212B2 (en) Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
US8101628B2 (en) Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880015768.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08747731

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008254319

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1825/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008747731

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008254319

Country of ref document: AU

Date of ref document: 20080507

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12598926

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20097023340

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/012228

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010508500

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2691997

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 200971068

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0811433

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091109